DARE vs. ACXP, VIRX, THTX, NRXP, SPRB, ENLV, IPA, FBIO, APRE, and ACST
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Acurx Pharmaceuticals (ACXP), Viracta Therapeutics (VIRX), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), Spruce Biosciences (SPRB), Enlivex Therapeutics (ENLV), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Aprea Therapeutics (APRE), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 5.3% of Daré Bioscience shares are held by company insiders. Comparatively, 35.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Daré Bioscience presently has a consensus price target of $4.50, indicating a potential upside of 934.96%. Acurx Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 455.56%. Given Daré Bioscience's higher possible upside, equities research analysts plainly believe Daré Bioscience is more favorable than Acurx Pharmaceuticals.
Acurx Pharmaceuticals' return on equity of -289.69% beat Daré Bioscience's return on equity.
Daré Bioscience has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.79, suggesting that its share price is 279% less volatile than the S&P 500.
Daré Bioscience received 343 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 91.67% of users gave Acurx Pharmaceuticals an outperform vote while only 73.29% of users gave Daré Bioscience an outperform vote.
In the previous week, Daré Bioscience had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 15 mentions for Daré Bioscience and 12 mentions for Acurx Pharmaceuticals. Daré Bioscience's average media sentiment score of 0.21 beat Acurx Pharmaceuticals' score of 0.07 indicating that Daré Bioscience is being referred to more favorably in the media.
Acurx Pharmaceuticals has lower revenue, but higher earnings than Daré Bioscience. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Daré Bioscience beats Acurx Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
